IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases, has appointed Dr. Alan Fu as Chief Financial Officer (CFO), reporting to Maxwell Wang, CEO, IASO Bio. Dr. Fu brings over two decades of experience in capital markets, financial management and scientific research, including most recently as managing director of Haitong International and director of Citigroup Global Markets.

As a member of the executive leadership team, Dr. Fu will oversee IASO Bio's capital markets activities and financial management, and will advance the company's sustainable development in capital markets and financial operations.

Dr. Fu combines rich experiences in finance with a deep knowledge in science. While at Haitong International and Citigroup he led numerous successful listings of Chinese companies in Hong Kong and the United States, including multiple companies in the healthcare industry. Prior to that, Dr. Fu worked for two law firms?Davis Polk & Wardwell in Hong Kong and Skadden, Arps, Slate, Meagher & Flom in Palo Alto?where he focused on capital markets transactions, including IPOs and bond issuances. Early in his career, he was a scientist at Rigel Pharmaceuticals, a US-based biotechnology company, focusing on research and drug development in the immunology and oncology areas.

Dr. Fu holds a J.D. degree from University of California, Berkeley School of Law, a Ph.D. degree in Molecular Genetics from Washington University School of Medicine in St. Louis, an M.S. degree in Molecular Immunology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences and a B.S. degree in Genetics and Genetic Engineering from Fudan University.

"The opportunity to serve on the executive team of a company like IASO Bio with its commitment to the development of novel cell therapies for oncology and autoimmune diseases and the delivery of cures to global patients and saving more lives was something I couldn't turn down," said Dr. Fu. "IASO Bio has been growing rapidly as several high-potential products have either been granted Breakthrough Therapy Designation (BTD) or had their Investigational New Drug (IND) applications accepted. I'm inspired and encouraged by these achievements and very glad to join this enterprising team at this key moment in its impressive growth journey. I hope my experience and knowledge in finance and science can help create more value for the company."

"Alan is a proven leader who brings a deep understanding of the healthcare industry and capital markets to the CFO role," said Dr. Wang. "I am very excited that he joins our leadership team at a time when IASO Bio is about to enter the commercialization stage and expand our global footprint. His appointment further strengthens our leadership team. We expect and believe his expertise, leadership and extensive industry network will propel the company to achieve important goals for the next stage!"

About IASO Bio

IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of 8 novel pipeline products, including IASO's leading asset, CT103A, an innovative anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory (R/R) multiple myeloma (RRMM). CT103A was granted Breakthrough Therapeutic Designation by China's National Medical Products Administration (NMPA) in February 2021. In addition. The company's in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy has received two IND clearances from NMPA for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in July 2021. For more information on IASO Bio, please visit www.iasobio.com.